TX-EMIST
2.11.2020 14:02:05 CET | Business Wire | Press release
EMist® Disinfection Solutions today announced the launch of the EX-7000 Tru Electrostatic™ Disinfectant Sprayer.
The EX-7000 is lightweight and ergonomic weighing in at just 14.9 pounds making it one-half lighter than other sprayers. Equipped with intelligent Charge Detect™ Technology, the EX-7000 electrostatic sprayer continuously detects the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue, ensuring the most comprehensive disinfectant coating in the industry, and reducing labor and chemical costs by 50 percent.
Disinfectant is first atomized, passes through an electrostatic-induction nozzle, charged using a bipolar power supply, and then discharged toward the target area. The bipolar supply causes the electrical charges to be alternatively redistributed, resulting in droplets having an excess of either positive or negative charges. These charged droplets are so attracted to the targeted area that they coat the sides, edges, and backside of surfaces.
EMist’s TruElectrostatic Disinfectant Sprayers are built on six core platforms, resulting in an electrostatic sprayer that provides 100 percent continuous electrostatic charge output, eliminates grounding, yielding superior, comprehensive coverage.
TruTechnology: EPIX Charge Detect Technology
Using EPIX Charge Detect Technology, the electrostatic sprayers continuously detect the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue. The discharged droplets wrap around surfaces. This wraparound effect creates an even, consistent and comprehensive coverage of chemical, reducing chemical and labor costs.
TruConfidence: Patented. Proven. Trusted.
Since the emergence of COVID-19, many companies have appeared overnight claiming they have electrostatic sprayers. When dealing with life-threatening pathogens, it’s critically important to know that the company you’re buying from is experienced, respected, and proven. EMist electrostatic sprayers are patented, backed by independent lab studies, used during the 2014 Ebola crisis, and developed by electrostatic industry veteran Mike Sides, who frequently works with the Department of Defense, Naval Entomology Center of Excellence, USDA, and the World Health Organization.
TruCharge: Best Performance
Electrostatic sprayer polarity matters. Most surfaces have a negative or neutral charge (the earth itself is negative). Per the EPA, electrostatic sprayers should impart a positive charge so that the positively charged disinfectant droplets are attracted to targeted negative or neutral surfaces. Positively charged droplets increase droplet adhesion and wrap.
TruDesign: Safer Operation
When spraying big areas, big buildings, or tight spaces, a cordless sprayer allows you to maneuver and move about freely. EMist sprayers are ergonomic, lightweight, and cordless. That means operators can take the sprayer to where the work needs to be done rather than relying on wall outlets at the work site. Portability is a clear advantage for any user who needs to go where the work is to get the job done right.
TruAssurance: User Safety
Per the EPA, electrostatic disinfectant sprayers should have a median droplet size greater than 40 microns. Droplets must be large enough to resist evaporation and drift but small enough that the droplets can change their trajectory when it comes close to a target. Most competitor sprayers produce droplets of less than 40 microns making them highly drift-prone and increasing user inhalation concerns. EMist sprayers maintain a median droplet size of 75 microns.
TruCost: Lower Total Cost of Ownership
Based on the need to disinfect large areas, manual application of disinfectants is a thing of the past. Electrostatic application is the new normal. Customers using EMist systems typically see up to 50 percent reduction in labor and chemical costs. Competitively priced, advanced and patented electrostatic technology, and proven performance provide an overall lower total cost of ownership.
EMist has announced a reservation program for purchasers who want to secure their units in December. The company will begin taking refundable $50 reservations on its official website starting on November 2 at 8 a.m. Central Time. The EX-7000 is available through EMist distributors at a list price of $3,995 USD.
About EMist
Headquartered in Fort Worth, Texas, EMist develops intelligent electrostatic disinfectant sprayers that make spaces healthier. For more information, visit EMist.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005026/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
